{"result": {"id": "chatcmpl-422", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "**Brolucizumab** is a novel anti-vascular endothelial growth factor (VEGF) drug currently under study for treating various eye conditions, including age-related macular degeneration (AMD). It is an anti-VEGF antibody that helps manage neovascular AMD, a condition where abnormal blood vessels grow in the retina. Brolucizumab can also be used to treat wet AMD and retinal diseases.  It is often referred to as IB and has been used to treat central serous retinopathy (CSR) secondary to autoimmune diseases such as uveitis or ankylosing spondylitis. \n\n\n**Note:** The descriptions mention \"type 3 neovascularizations\" and \"MNV,\" which are likely referring to the same condition, medical neovascularization.  \n", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1743185944, "model": "gemma2:2b", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_ollama", "usage": {"completion_tokens": 154, "prompt_tokens": 329, "total_tokens": 483, "completion_tokens_details": null, "prompt_tokens_details": null}}, "input": {"messages": [{"content": "\nYou are a helpful assistant responsible for generating a comprehensive summary of the data provided below.\nGiven one or two entities, and a list of descriptions, all related to the same entity or group of entities.\nPlease concatenate all of these into a single, comprehensive description. Make sure to include information collected from all the descriptions.\nIf the provided descriptions are contradictory, please resolve the contradictions and provide a single, coherent summary.\nMake sure it is written in third person, and include the entity names so we have the full context.\n\n#######\n-Data-\nEntities: \"BROLUCIZUMAB\"\nDescription List: [\"**Brolucizumab** is a novel anti-vascular endothelial growth factor (VEGF) drug being tested for treating **type 3 neovascularizations** and **AMD**. It is specifically used to treat **MNV**, which stands for **medical neovascularization**.  Brolucizumab is also known as a medication used to treat **AMD**. \\n\", \"Brolucizumab is a medication currently under study for treating various eye conditions, including certain forms of age-related macular degeneration (AMD). It is an anti-VEGF antibody that helps manage neovascular AMD, a condition where abnormal blood vessels grow in the retina. Brolucizumab can also be used to treat wet AMD and retinal diseases.  It is often referred to as IB and has been used to treat central serous retinopathy (CSR) secondary to autoimmune diseases such as uveitis or ankylosing spondylitis. \\n\"]\n#######\nOutput:\n", "role": "user"}], "parameters": {"model": "gemma2:2b", "frequency_penalty": 0.0, "max_tokens": 500, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_summarize_c5ed5b95a78712f6fcda2aa66765828520b0fe1047d47461e311dc16c27174f5_v2"}